Jee Youn Oh1, Juwhan Choi1, Sangmi Chung1, Young Seok Lee1, Kyung Hoon Min1, Gyu Young Hur1, Sung Yong Lee1, Jae Jeong Shim1 and Kyung Ho Kang1
Medicine, Korea University Guro Hospital, Seoul, Republic of Korea
Combined pulmonary fibrosis and emphysema (CPFE) is characterized by
upper lung predominant emphysema and lower lung predominant fibrosis.
However, optimal treatment of CPFE is not well known.
e reviewed the lung function change after CPFE treatment to evaluate
reviewed medical records of CPFE patients in Korea University Guro
Hospital for 10 years. We evaluated pulmonary function test (FEV1,
FVC, DLCO/VA, composite physiologic index [CPI;
91- (0.65?%predicted DLco) ?
(0.53?%predicted FVC) + (0.34?%predicted FEV1)]
at baseline and after 24months) and treatment of CPFE patients.
Thirty-nine CPFE patients treated as chronic obstructive pulmonary
disease (COPD) or idiopathic pulmonary fibrosis (IPF) were analyzed.
Among them, 13 patients were treated as COPD with long acting
muscarinic antagonist (LAMA) and 12 patients were treated as IPF with
steroid, other immunosuppressants or colchine. CPI changes within 24
months were lower with patients treated with COPD
(17.99?13.70 with COPD treatment, 7.09?17.72
without COPD treatment, p=0.041). However, DLCO/VA
change within 24 months (2.80?18.16 with IPF treatment,
24.25?17.10 without IPF treatment, p=0.002)
and CPI change within 24 months (11.05?17.28 with IPF
treatment, 21.81?8.37 without IPF treatment, p
=0.048) were rather higher with patients treated with IPF.
Patients treated as COPD with inhaled bronchodilator showed improvement
in CPI. However, when treated as IPF with immunosuppressants, DLCO/VA
and CPI after 24 months rather aggravated. Although this is a
retrospective and limited data, patients with CPFE may get benefit when
properly treated as COPD with proper long acting inhaled bronchodilator.